GLP-1 Agonists, Willpower, and Weight Stigma: A Paradigm Shift for Obesity

Authors

  • Pablo Arrona-Cardoza McGill University

DOI:

https://doi.org/10.18192/uojm.v15iS2.7526

Keywords:

GLP-1 agonist, weight, obesity

References

1. NCD Risk Factor Collaboration. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431):1027-50. Epub 20240229. doi: 10.1016/s0140-6736(23)02750-2. PubMed PMID: 38432237; PubMed Central PMCID: PMC7615769.

2. Statistics Canada [Internet]. Table 13-10-0096-01 Health characteristics, annual estimates. Available from: https://doi.org/10.25318/1310009601-eng

3. Fruh SM. Obesity: Risk factors, complications, and strategies for sustainable long-term weight management. J Am Assoc Nurse Pract. 2017;29(S1):S3-S14. doi: 10.1002/2327-6924.12510. PubMed PMID: 29024553; PubMed Central PMCID: PMC6088226.

4. Tremmel M, Gerdtham UG, Nilsson PM, Saha S. Economic Burden of Obesity: A Systematic Literature Review. Int J Environ Res Public Health. 2017;14(4). Epub 20170419. doi: 10.3390/ijerph14040435. PubMed PMID: 28422077; PubMed Central PMCID: PMC5409636.

5. Taillie LS, Bercholz M, Popkin B, Reyes M, Colchero MA, Corvalán C. Changes in food purchases after the Chilean policies on food labelling, marketing, and sales in schools: a before and after study. Lancet Planet Health. 2021;5(8):e526-e33. doi: 10.1016/s2542-5196(21)00172-8. PubMed PMID: 34390670; PubMed Central PMCID: PMC8364623.

6. Wadden TA, Tronieri JS, Butryn ML. Lifestyle modification approaches for the treatment of obesity in adults. Am Psychol. 2020;75(2):235-51. doi: 10.1037/amp0000517. PubMed PMID: 32052997; PubMed Central PMCID: PMC7027681.

7. Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg. 2014;149(3):275-87. doi: 10.1001/jamasurg.2013.3654. PubMed PMID: 24352617; PubMed Central PMCID: PMC3962512.

8. Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201-23. Epub 20211123. doi: 10.1038/s41573-021-00337-8. PubMed PMID: 34815532; PubMed Central PMCID: PMC8609996.

9. Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. Epub 20190930. doi: 10.1016/j.molmet.2019.09.010. PubMed PMID: 31767182; PubMed Central PMCID: PMC6812410.

10. Drucker DJ. The GLP-1 journey: from discovery science to therapeutic impact. The Journal of Clinical Investigation. 2024;134(2). doi: 10.1172/JCI175634.

11. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Epub 20210210. doi: 10.1056/NEJMoa2032183. PubMed PMID: 33567185.

12. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-32. Epub 20231111. doi: 10.1056/NEJMoa2307563. PubMed PMID: 37952131.

13. Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069-84. Epub 20230825. doi: 10.1056/NEJMoa2306963. PubMed PMID: 37622681.

14. Jastreboff AM, Aronne LJ, Stefanski A. Tirzepatide Once Weekly for the Treatment of Obesity. Reply. N Engl J Med. 2022;387(15):1434-5. doi: 10.1056/NEJMc2211120. PubMed PMID: 36239655.

15. Trinh D, McDonald M, Authors. Formulary Management of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: Environmental Scan. 2024.

16. Agri-Food Analytics Lab. GLP1 Survey: Impact of GLP-1 Drugs on Consumer Eating Habits and Food Industry Trends Dalhousie University; 2024. Available from: https://www.dal.ca/sites/agri-food/research/glp1-survey.html.

17. Post SM, Persky S. The effect of GLP-1 receptor agonist use on negative evaluations of women with higher and lower body weight. Int J Obes (Lond). 2024;48(7):1019-26. Epub 20240401. doi: 10.1038/s41366-024-01516-4. PubMed PMID: 38561488.

18. Pew Research Center [Internet]. “How Americans View Weight-Loss Drugs and Their Potential Impact on Obesity in the U.S.; 2023. Available from: https://www.pewresearch.org/science/2024/02/26/how-americans-view-weight-loss-drugs-and-their-potential-impact-on-obesity-in-the-u-s/.

19. Westbury S, Oyebode O, van Rens T, Barber TM. Obesity Stigma: Causes, Consequences, and Potential Solutions. Curr Obes Rep. 2023;12(1):10-23. Epub 20230214. doi: 10.1007/s13679-023-00495-3. PubMed PMID: 36781624; PubMed Central PMCID: PMC9985585.

20. Steele M, Finucane FM. Philosophically, is obesity really a disease? Obesity Reviews. 2023;24(8):e13590. doi: https://doi.org/10.1111/obr.13590.

21. Schwartz MW, Seeley RJ, Zeltser LM, Drewnowski A, Ravussin E, Redman LM, et al. Obesity Pathogenesis: An Endocrine Society Scientific Statement. Endocrine Reviews. 2017;38(4):267-96. doi: 10.1210/er.2017-00111.

22. Purnell JQ, le Roux CW. Hypothalamic control of body fat mass by food intake: The key to understanding why obesity should be treated as a disease. Diabetes Obes Metab. 2024;26 Suppl 2:3-12. Epub 20240214. doi: 10.1111/dom.15478. PubMed PMID: 38351898.

23. Grannell A, Fallon F, Al-Najim W, le Roux C. Obesity and responsibility: Is it time to rethink agency? Obes Rev. 2021;22(8):e13270. Epub 20210512. doi: 10.1111/obr.13270. PubMed PMID: 33977636.

24. Hayashi D, Edwards C, Emond JA, Gilbert-Diamond D, Butt M, Rigby A, et al. What Is Food Noise? A Conceptual Model of Food Cue Reactivity. Nutrients. 2023;15(22). Epub 20231117. doi: 10.3390/nu15224809. PubMed PMID: 38004203; PubMed Central PMCID: PMC10674813.

25. Wharton S, Davies M, Dicker D, Lingvay I, Mosenzon O, Rubino DM, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med. 2022;134(1):14-9. Epub 20211129. doi: 10.1080/00325481.2021.2002616. PubMed PMID: 34775881.

26. Cassatha, C. Ozempic Can Cause Major Loss of Muscle Mass and Reduce Bone Density [Internet]. Healthline; 2023. Available from: https://www.healthline.com/health-news/ozempic-muscle-mass-loss

27. Ruegsegger GN, Booth FW. Health Benefits of Exercise. Cold Spring Harb Perspect Med. 2018;8(7). Epub 20180702. doi: 10.1101/cshperspect.a029694. PubMed PMID: 28507196; PubMed Central PMCID: PMC6027933.

28. Guthold R, Stevens GA, Riley LM, Bull FC. Worldwide trends in insufficient physical activity from 2001 to 2016: a pooled analysis of 358 population-based surveys with 1·9 million participants. Lancet Glob Health. 2018;6(10):e1077-e86. Epub 20180904. doi: 10.1016/S2214-109X(18)30357-7. PubMed PMID: 30193830.

29. Walsh JM, Swangard DM, Davis T, McPhee SJ. Exercise counseling by primary care physicians in the era of managed care. Am J Prev Med. 1999;16(4):307-13. doi: 10.1016/s0749-3797(99)00021-5. PubMed PMID: 10493287.

30. Fowles JR, O'Brien MW, Solmundson K, Oh PI, Shields CA. Exercise is Medicine Canada physical activity counselling and exercise prescription training improves counselling, prescription, and referral practices among physicians across Canada. Appl Physiol Nutr Metab. 2018;43(5):535-9. Epub 20180109. doi: 10.1139/apnm-2017-0763. PubMed PMID: 29316409.

31. Sprys-Tellner T, Levine D, Kagzi A. The Application of Exercise Prescription Education in Medical Training. J Med Educ Curric Dev. 2023;10:23821205231217893. Epub 20231128. doi: 10.1177/23821205231217893. PubMed PMID: 38033378; PubMed Central PMCID: PMC10685795.

32. Foster D, Sanchez-Collins S, Cheskin LJ. Multidisciplinary Team-Based Obesity Treatment in Patients With Diabetes: Current Practices and the State of the Science. Diabetes Spectr. 2017;30(4):244-9. doi: 10.2337/ds17-0045. PubMed PMID: 29151714; PubMed Central PMCID: PMC5687103.

33. Talumaa B, Brown A, Batterham RL, Kalea AZ. Effective strategies in ending weight stigma in healthcare. Obes Rev. 2022;23(10):e13494. Epub 20220807. doi: 10.1111/obr.13494. PubMed PMID: 35934011; PubMed Central PMCID: PMC9540781.

Downloads

Published

2025-08-05

Issue

Vol. 15 No. S2 (2025): UOJM Commentary Contest 2024

Section

Commentary

License

Copyright (c) 2025 Pablo Arrona-Cardoza

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

  1. Authors publishing in the UOJM retain copyright of their articles, including all the drafts and the final published version in the journal.
  2. While UOJM does not retain any rights to the articles submitted, by agreeing to publish in UOJM, authors are granting the journal right of first publication and distribution rights of their articles.
  3. Authors are free to submit their works to other publications, including journals, institutional repositories or books, with an acknowledgment of its initial publication in UOJM.
  4. Copies of UOJM are distributed both in print and online, and all materials will be publicly available online. The journal holds no legal responsibility as to how these materials will be used by the public.
  5. Please ensure that all authors, co-authors and investigators have read and agree to these terms.
  6. Works are  licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.